In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards' Winning Heart Valve Strategy

Executive Summary

Edwards Lifesciences' strategy of divesting slow-growing businesses and focusing on the relatively underserved niche of late-stage (or what the company now calls advancing stage) cardiovascular disease appears to be paying off. Now the leader in the heart valve market, the company believes that the pressures cardiac surgeons are feeling, coupled with the introduction of devices like drug-eluting stents, might open up new opportunities as surgeons turn to other ways to add value to the treatment of patients with cardiovascular disease.

You may also be interested in...



Edwards: Transcatheter Valve Leader Proves You Can Go Home Again

After exploring a number of new product markets to drive growth in the decade since its spin-off from Baxter, Edwards has found its sweet spot in its own backyard: heart valves. Through an aggressive early acquisition, the company has emerged as the leader in what looks to be the next major device product market: - transcatheter valves. But in building a transcatheter valve business, Edwards must maintain its surgical customers while also selling to new physician customers: interventionalist cardiologists - a clinical specialty with a history of competing with surgery.

In Brief January 2007

A brief summary of recent product developments in the device industry, including updates on Edwards Lifesciences, Cardiophonics, Boston Scientific. Also, short takes on the Pediatric Medical Device Safety and Improvement Act, and Annual Breast Cancer Screening.

Edwards Lifesciences: Staking New Ground in Cardiovascular Devices

Over the past seven years, since its spin off from Baxter International, Edwards Lifesciences has built a cardiovascular business to challenge the industry giants. In this interview, CEO Mike Mussallem looks back over a 20-year career whose highlights include surviving the Baxter/American Hospital Supply merger and formulating Edwards' vision.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV001873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel